The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with CLL
Paul Hampel, MD, Mayo Clinic, Rochester, MN, addresses the safety concerns associated with concomitant radiotherapy delivery for second primary malignancy in patients with chronic lymphocytic leukemia (CLL) treated with continuous novel agents. Dr Hampel discusses the findings of a retrospective analysis using data from patients treated concomitantly in routine clinical practice, and determined that there was not a heightened risk of toxicity from either a radiation perspective or from the perspective of the CLL-directed treatment. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
